CS
RIGL icon

Candriam SCA’s Rigel Pharmaceuticals RIGL Stock Holding History

Candriam SCA’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-142,963
Closed -$1.61M – 890
2022
Q2 		$1.61M Hold
142,963
– – 0.01% 547
2022
Q1 		$4.27M Sell
142,963
-79,207
-36% -$2.14M 0.03% 380
2021
Q4 		$5.89M Hold
222,170
– – 0.04% 328
2021
Q3 		$8.06M Hold
222,170
– – 0.05% 312
2021
Q2 		$9.64M Buy
+222,170
New +$8.39M 0.07% 291
2020
Q4 		– Sell
-28,000
Closed -$672K – 842
2020
Q3 		$672K Sell
28,000
-166,300
-86% -$4.08M 0.01% 678
2020
Q2 		$3.56M Sell
194,300
-50,000
-20% -$900K 0.04% 399
2020
Q1 		$5.11M Hold
244,300
– – 0.06% 338
2019
Q4 		$5.23M Sell
244,300
-3,500
-1% -$72.1K 0.06% 345
2019
Q3 		$4.63M Buy
+247,800
New +$5.12M 0.06% 334
2019
Q2 		– Sell
-247,800
Closed -$5.59M – 134
2019
Q1 		$6.37M Hold
247,800
– – 0.08% 270
2018
Q4 		$5.7M Buy
247,800
+21,000
+9% +$593K 0.09% 258
2018
Q3 		$7.28M Buy
226,800
+69,800
+44% +$2.1M 0.1% 246
2018
Q2 		$4.44M Buy
157,000
+6,500
+4% +$231K 0.07% 319
2018
Q1 		$5.33M Buy
150,500
+28,500
+23% +$1.14M 0.09% 271
2017
Q4 		$4.73M Sell
122,000
-4,500
-4% -$171K 0.08% 276
2017
Q3 		$3.21M Buy
126,500
+8,500
+7% +$207K 0.06% 361
2017
Q2 		$3.22M Buy
118,000
+9,500
+9% +$260K 0.06% 362
2017
Q1 		$3.59M Buy
108,500
+47,000
+76% +$1.2M 0.07% 331
2016
Q4 		$1.46M Sell
61,500
-11,000
-15% -$315K 0.03% 430
2016
Q3 		$2.66M Buy
+72,500
New +$2.08M 0.06% 301

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Candriam SCA's RIGL Position: Q3 2022 in Review

Candriam SCA sold out of Rigel Pharmaceuticals (RIGL) in Q3 2022, closing a stake of 142,963 shares — an estimated $1.61M sold.

Candriam SCA first reported a position in RIGL in Q3 2016 and held it in 21 quarters. The position peaked at $9.64M in Q2 2021. 138 funds tracked by Wall St. Rank hold RIGL as of Q3 2022.

  • Candriam SCA reported no remaining Rigel Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Candriam SCA sold 142,963 Rigel Pharmaceuticals shares in Q3 2022, an estimated $1.61M.
  • Candriam SCA first reported a position in Rigel Pharmaceuticals in Q3 2016 and held it in 21 quarters.
  • Candriam SCA's Rigel Pharmaceuticals position peaked at $9.64M in Q2 2021.
  • 138 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2022.

Based on Candriam SCA's 13F filing for Q3 2022, filed 10 Nov 2022.